<PAGE>
--------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of
The Securities Act of 1934
Date of Report (Date of earliest event reported): AUGUST 1, 2000
TECHNICLONE CORPORATION
(Exact name of registrant as specified in its charter)
DELAWARE 000-17085 95-3698422
(State or other (Commission (I.R.S. Employer
jurisdiction File Number) Identification No.)
of incorporation)
14282 FRANKLIN AVENUE
TUSTIN, CALIFORNIA 92780-7017
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (714) 508-6000
--------------------------------------------------------------------------------
<PAGE>
ITEM 5. OTHER EVENTS.
On August 1, 2000, Techniclone Corporation, a Delaware corporation (the
"Registrant"), entered into a licensing agreement (the "Agreement") for a
segment of its Vascular Targeting Agent (VTA) technology, specifically related
to applications of Photodynamic Therapy agents (PDT) with Scotia Pharmaceuticals
Limited. The Registrant's press release announcing the Agreement is attached as
Exhibit 99.2.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(c) Exhibits.
Exhibit Name of Exhibit
------- ---------------
99.2 Press Release of Registrant dated August 1, 2000.
2
<PAGE>
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
TECHNICLONE CORPORATION
Date: August 3, 2000 By: /s/ John N. Bonfiglio
-------------------------------------
John N. Bonfiglio,
President and Chief Executive Officer
3
<PAGE>
EXHIBIT INDEX
Exhibit Name of Exhibit
------- ---------------
99.2 Press Release dated August 1, 2000.
4
